Abstracts tagged "Scleredema"

Abstract Number: 903 • 2013 ACR/ARHP Annual Meeting
A Qualitative Study Of The Educational Needs Of Children With Scleroderma and Their Parents
Cindy F. Mendelson¹, Ana-Alicia Huerta², Jane Kastning³, Bernadette Vargas³ and Janet L. Poole⁴, ¹College of Nursing, University of New Mexico, Albuquerque, NM, ²Univeristy of New Mexico, Albuquerque, NM, ³Occupational Therapy, University of New Mexico, Albuquerque, NM, ⁴Occupational Therapy Program, University of New Mexico, Albuquerque, NM
Background/Purpose: Scleroderma is a rare disease, especially in childhood. Skin changes can be physically disfiguring which can lead to lowered self-esteem, especially during the adolescent…
Abstract Number: 820 • 2013 ACR/ARHP Annual Meeting
CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Jörg HW Distler¹, Yongqing Wang², Pawel Zerr³, Katrin Palumbo⁴, Gerald Horan⁵, Peter Schafer⁵ and Bashar Kahaleh⁶, ¹Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medicine, University of Toledo, Toledo, OH, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ, ⁶Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disease in which B cells may play a crucial role in pathogenesis. CC-220 is an immunomodulatory drug…
Abstract Number: 667 • 2013 ACR/ARHP Annual Meeting
IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Rebecca Alade¹, Korsa Khan², Xu Shiwen³, Christopher P. Denton⁴ and Voon Ong⁵, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ³Rheumatology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁵Department of Rheumatology, UCL Medical School, London, England
Background/Purpose: IL6 is a key mediator recently implicated in activation of extracellular matrix (ECM) proteins in scleroderma (SSc) fibroblasts. CCL2 is a proinflammatory chemokine that…
Abstract Number: 660 • 2013 ACR/ARHP Annual Meeting
Bleomycin Delivery By Mini-Osmotic Pump: A Novel Multi-Organ Murine Model For Fibrosis
Rebecca Lee¹, Elena Tourkina², Richard P. Visconti³ and Stanley Hoffman⁴, ¹Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Rheumatology, Medical University of SC, Charleston, SC, ³Cell Biology and Regenerative Medicine, Medical University of South Carolina, Charleston, SC, ⁴Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc, Scleroderma) is a rare but severe systemic connective tissue disorder involving the skin and multiple internal organs, in particular lung, kidney,…
Abstract Number: 155 • 2013 ACR/ARHP Annual Meeting
Exome Sequencing For Identification Of Potential Causal Variants For Diffuse Cutaneous Systemic Sclerosis
Angel CY Mak¹, M Kari Connolly², Tamiko Katsumoto^3,4, Paul Wolters⁵, Clare Cleveland^3,4, Blanca M Herrera¹, Paul LF Tang¹, Simi Mathauda¹, Richard Lao¹, Pui-Yan Kwok^1,2 and Lindsey A. Criswell^3,4, ¹University of California, San Francisco, Institute for Human Genetics, San Francisco, CA, ²University of California, San Francisco, Department of Dermatology, San Francisco, CA, ³University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴University of California, San Francisco, Department of Medicine, San Francisco, CA, ⁵University of California, San Francisco, Department of Medicine, Pulmonary Division, San Francisco, CA
Background/Purpose: Scleroderma is a genetically complex autoimmune disease with substantial phenotypic heterogeneity. Previous genome-wide association studies (GWAS) have identified a large number of gene regions…
Abstract Number: 2918 • 2013 ACR/ARHP Annual Meeting
Survival After Lung Transplantation In Systemic Sclerosis. A Systematic Review
Irfan Y. Khan¹, Lianne G. Singer², Marc de Perrot³, John T. Granton⁴, Shaf Keshavjee³, Cathy Chau⁵, Amie T. Kron⁶ and Sindhu R. Johnson⁷, ¹Medicine, Pulmonary Hypertension Programme, University Health Network, University of Toronto, Toronto, ON, Canada, ²Medicine, Division of Respirology, University of Toronto; and Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Medicine, Toronto Lung Transplant Program, Division of Thoracic Surgery, University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ⁵Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Lung transplantation is a life-saving option for systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) and interstitial lung disease (SSc-ILD) patients. Yet, there is risk…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.